539 related articles for article (PubMed ID: 30181243)
21. Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase).
Ilinskaya ON; Singh I; Dudkina E; Ulyanova V; Kayumov A; Barreto G
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1559-67. PubMed ID: 27066977
[TBL] [Abstract][Full Text] [Related]
22. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.
Alem D; Yang X; Beato F; Sarcar B; Tassielli AF; Dai R; Hogenson TL; Park MA; Jiang K; Cai J; Yuan Y; Fernandez-Zapico ME; Tan AC; Fleming JB; Xie H
Mol Carcinog; 2023 Jul; 62(7):1025-1037. PubMed ID: 37042566
[TBL] [Abstract][Full Text] [Related]
23. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
24. Ras-guanine nucleotide exchange factor sos2 is dispensable for mouse growth and development.
Esteban LM; Fernández-Medarde A; López E; Yienger K; Guerrero C; Ward JM; Tessarollo L; Santos E
Mol Cell Biol; 2000 Sep; 20(17):6410-3. PubMed ID: 10938118
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.
Rosenberger G; Meien S; Kutsche K
Hum Mutat; 2009 Mar; 30(3):352-62. PubMed ID: 19035362
[TBL] [Abstract][Full Text] [Related]
26. SOS2 regulates the threshold of mutant
Theard PL; Linke AJ; Sealover NE; Daley BR; Yang J; Cox K; Kortum RL
bioRxiv; 2023 Jun; ():. PubMed ID: 37425733
[TBL] [Abstract][Full Text] [Related]
27. The Role of Wild-Type RAS in Oncogenic RAS Transformation.
Sheffels E; Kortum RL
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33924994
[TBL] [Abstract][Full Text] [Related]
28. SOS GEFs in health and disease.
Baltanás FC; Zarich N; Rojas-Cabañeros JM; Santos E
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188445. PubMed ID: 33035641
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Smith CR; Chen D; Christensen JG; Coulombe R; Féthière J; Gunn RJ; Hollander J; Jones B; Ketcham JM; Khare S; Kuehler J; Lawson JD; Marx MA; Olson P; Pearson KE; Ren C; Tsagris D; Ulaganathan T; Van't Veer I; Wang X; Ivetac A
J Med Chem; 2024 Jan; 67(1):774-781. PubMed ID: 38156904
[TBL] [Abstract][Full Text] [Related]
30. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.
Quinlan MP; Quatela SE; Philips MR; Settleman J
Mol Cell Biol; 2008 Apr; 28(8):2659-74. PubMed ID: 18268007
[TBL] [Abstract][Full Text] [Related]
31. Wild-type NRas and KRas perform distinct functions during transformation.
Fotiadou PP; Takahashi C; Rajabi HN; Ewen ME
Mol Cell Biol; 2007 Oct; 27(19):6742-55. PubMed ID: 17636015
[TBL] [Abstract][Full Text] [Related]
32. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
Counter C
Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.
Barceló C; Paco N; Morell M; Alvarez-Moya B; Bota-Rabassedas N; Jaumot M; Vilardell F; Capella G; Agell N
Cancer Res; 2014 Feb; 74(4):1190-9. PubMed ID: 24371225
[TBL] [Abstract][Full Text] [Related]
34. Comparison of liver oncogenic potential among human RAS isoforms.
Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
[TBL] [Abstract][Full Text] [Related]
35. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.
Vicent S; Chen R; Sayles LC; Lin C; Walker RG; Gillespie AK; Subramanian A; Hinkle G; Yang X; Saif S; Root DE; Huff V; Hahn WC; Sweet-Cordero EA
J Clin Invest; 2010 Nov; 120(11):3940-52. PubMed ID: 20972333
[TBL] [Abstract][Full Text] [Related]
36. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
[TBL] [Abstract][Full Text] [Related]
37. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.
Theard PL; Linke AJ; Sealover NE; Daley BR; Yang J; Cox K; Kortum RL
Mol Oncol; 2024 Mar; 18(3):641-661. PubMed ID: 38073064
[TBL] [Abstract][Full Text] [Related]
38. MTH1 expression is required for effective transformation by oncogenic HRAS.
Giribaldi MG; Munoz A; Halvorsen K; Patel A; Rai P
Oncotarget; 2015 May; 6(13):11519-29. PubMed ID: 25893378
[TBL] [Abstract][Full Text] [Related]
39. Activation of Ras-dependent signaling pathways by G(14) -coupled receptors requires the adaptor protein TPR1.
Kwan DH; Yung LY; Ye RD; Wong YH
J Cell Biochem; 2012 Nov; 113(11):3486-97. PubMed ID: 22711498
[TBL] [Abstract][Full Text] [Related]
40. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]